[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Ecuador\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":734},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,45,77,106,140,173,202,232,257,296,328,352,385,410,436,471,494,524,553,584,607,630,653,677,706],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100618586","registry-study-for-the-evaluation-of-high-risk-cardiac-patients-by-willem-ai-based-ecg-platform-100618586",false,"NCT07333547","Registry Study for the Evaluation of High-risk Cardiac Patients by WILLEM AI-based ECG Platform","WILLEMRegistry","Inclusion Criteria:\n\n* EC\u002FIRB approval of ICF waiver prior to recruitment; otherwise, signed informed consent form by subject and investigator\n* Age \\> 18 years-old, with no upper limit\n* Subjects undergoing standard of care electrocardiogram (ECG) of any duration from any hardware device\n* All available, but at least one, legible ECG tracings in raw data format (e.g. DICOM, XML, EDF, JSON, HL7, SCP, WFDB, CSV, etc.)\n* Available subject clinical data associated with the ECG\n* For 12-lead ECGs, a minimum length of 10 seconds at a minimum sample frequency of 250 Hz\n* For ECGs from Holters, wearables, patches, insertable cardiac monitors, telemetries, etc., a minimum length of 30 seconds at a minimum sample frequency of 200 Hz with a lead I \u002F II or its MCL-DII lead approximation\n* For prospective eligibility only:\n* Signed informed consent form, unless previously waived by the EC\u002FIRB\n* Site technical viability for ECG and subject clinical data transfer (e.g. end-to-end integration following interoperability standards such as FHIR, HL7 or DICOM)\n\nExclusion Criteria:\n\n* Unavailable or suboptimal quality of the raw data from the ECG signal\n* Age \\\u003C 18 years-old",true,"ALL","18 Years",{"count":20,"type":21},200000,"ESTIMATED","OBSERVATIONAL","The WILLEM Registry is a large-scale, single-group, observational, registry study to collect continuous clinical evidence of Willem in real-world settings. Cardiovascular diseases are a major problem for public health and healthcare systems. Electrocardiograms (ECGs) are simple tests which increase diagnostic performance and early detection of cardiovascular diseases. However, its interpretation is complex, time consuming for cardiology experts, and entails high costs for healthcare systems. Willem allows AI-based automatic interpretation and its performance has been examined in previous clinical trials, but additional clinical evidence is needed for its integration in real-world clinical settings. This study will collect clinical evidence of Willem performance to detect cardiac abnormalities in ECGs from high-risk cardiac patients admitted to cardiovascular units.",[25],"High-risk Cardiac Patients",[27,28,29,30,31],"artificial intelligence","electrocardiogram","deep learning","cardiac disease","registry","RECRUITING","2026-07-17",{"date":35,"type":36},"2026-07-20","ACTUAL",{"date":38,"type":36},"2026-02-03",{"date":40,"type":21},"2036-01",{"name":42,"class":43},"Idoven 1903 S.L.","INDUSTRY",5,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100566920","bone-augmentation-techniques-in-the-mandible-posterior-region-100566920","NCT06661447","Bone Augmentation Techniques in the Mandible Posterior Region","Comparison of Bone Augmentation Techniques in the Mandibular Posterior Region: A Randomized Clinical Trial","Inclusion Criteria:\n\nPosterior mandibular edentulism requiring horizontal ridge augmentation (Cawood \\& Howell Classes IV-VI).\n\nOne or two eligible posterior mandibular sites suitable for cortical shell augmentation.\n\nAdequate residual bone height to allow safe fixation above the mandibular canal.\n\nGood general health (ASA I or II). Plaque index \\\u003C 20% and absence of active periodontal infection. Ability and willingness to attend scheduled follow-up visits (up to 12 months). Written informed consent provided prior to any study-related procedure.\n\nExclusion Criteria:\n\nUncontrolled systemic diseases affecting bone healing (e.g., uncontrolled diabetes mellitus, immunosuppressive disorders).\n\nCurrent heavy smoking (\\>5 cigarettes\u002Fday). Pregnancy or lactation. Current use of medications known to affect bone metabolism or healing (e.g., bisphosphonates, long-term corticosteroids, anticoagulants).\n\nActive periodontal disease or untreated oral infection. History of chemotherapy or radiotherapy to the head and neck region.","64 Years",{"count":54,"type":21},78,"INTERVENTIONAL",[57],"NA","This study will compare three methods to rebuild lost bone in the back part of the lower jaw (posterior mandible) before dental implant placement. Seventy-eight adults will be randomly assigned to receive one of three \"cortical shell\" techniques using either the patient's own bone (autogenous) or prefabricated bone plates from animal (xenogeneic) or human donors (allogeneic). In all groups, the space inside the shell will be filled with a mixture of small bone chips and bone substitute material. The main outcome is the increase in jawbone width measured on 3D cone-beam CT scans at 6 months after surgery. Additional scans and clinical assessments up to 12 months will evaluate healing, bone stability, and postoperative recovery.",[60,61],"Bone Substitutes","Alveolar Bone Grafting",[63,60,64],"Alveolar Bone Atrophy","Bone Resorption","NOT_YET_RECRUITING","2026-07-14",{"date":68,"type":36},"2026-07-16",{"date":70,"type":21},"2026-08-01",{"date":72,"type":21},"2027-04-01",{"name":74,"class":75},"Universidad de Especialidades Espiritu Santo","OTHER",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":55,"phases":89,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":76},"100638159","clinical-performance-and-quality-of-life-of-3d-printed-complete-dentures-under-digital-vs-hybrid-workflows-a-randomized-crossover-trial-100638159","NCT07626827","Clinical Performance and Quality of Life of 3D-Printed Complete Dentures Under Digital vs Hybrid Workflows: A Randomized Crossover Trial","Clinical Success, Oral Health-Related Quality of Life, and Relationship Between Maximum Masticatory Force and Denture Wear in Complete Dentures Fabricated by Additive Manufacturing Under Digital and Hybrid Workflows: A Prospective Randomized Crossover Clinical Trial","PRINT-DENT","Inclusion Criteria:\n\n* Completely edentulous (bimaxillary)\n* Age between 50 and 90 years\n* Able to understand and sign informed consent\n* No cognitive or psychological deficits that interfere with study participation\n\nExclusion Criteria:\n\n* Unimaxillary edentulism\n* Presence of Kelly syndrome\n* Presence of flabby tissue on alveolar ridges\n* No prior experience with complete dentures\n* Chronic motor disorders that may compromise prosthetic function","50 Years","90 Years",{"count":88,"type":21},20,[57],"This prospective randomized crossover clinical trial evaluates and compares the clinical performance and oral health-related quality of life (OHRQoL) of complete dentures fabricated through two additive manufacturing workflows - digital and hybrid - in edentulous patients attending the Dental Clinic of Universidad de Especialidades Espíritu Santo (UEES), Samborondón, Ecuador.\n\nIn the digital workflow, complete dentures are fabricated using direct intraoral scanning of edentulous ridges, CAD design, and 3D printing. In the hybrid workflow, conventional functional impressions are digitized, followed by CAD design and additive manufacturing of the definitive dentures.\n\nEach eligible participant receives two complete denture sets in a randomized crossover sequence (no washout period): Denture Set 1 is worn for 2 months, after which the participant crosses over to Denture Set 2, worn for an additional 2 months. Total active follow-up per participant is approximately 4 months. Following completion of the crossover phase, denture wear is monitored longitudinally for 12 months from the insertion of the second denture set (total study duration approximately 16 months per participant).\n\nThe study addresses three specific objectives:\n\nTo determine the clinical success rate of complete dentures fabricated by additive manufacturing under digital and hybrid workflows, evaluating retention, stability, denture base adaptation, occlusal balance, and need for clinical adjustments.\n\nTo evaluate the impact of complete denture treatment on OHRQoL using the validated OHIP-EDENT questionnaire, assessed at the insertion of each denture set and at the 2-month control of each period (4 measurement points total).\n\nTo evaluate the relationship between maximum masticatory force (T-Scan digital occlusal analysis system) and denture wear (volumetric 3D digital metrology via STL superimposition), with wear monitored over 12 months from insertion of the second denture set.",[92],"Complete Edentulism",[94,95,96,97],"hybrid workflow","complete denture","digital workflow","complete edentulous","2026-07-09",{"date":100,"type":36},"2026-07-13",{"date":102,"type":36},"2026-07-01",{"date":104,"type":21},"2027-11-30",{"name":74,"class":75},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":115,"conditions":116,"keywords":122,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100642154","volume-removal-intolerance-during-net-ultrafiltration-in-acute-kidney-injury-patients-100642154","NCT07643597","Volume Removal Intolerance During Net Ultrafiltration in Acute Kidney Injury Patients","VINKO","Inclusion Criteria:\n\n* Age ≥18 years\n* Admission to an Intensive Care Unit\n* Acute kidney injury according to KDIGO criteria\n* Prescription of continuous renal replacement therapy (CRRT) with net ultrafiltration\n* Clinical stability considered sufficient to initiate net ultrafiltration according to the treating clinical team\n\nExclusion Criteria:\n\n* Chronic kidney replacement therapy prior to ICU admission\n* Pregnancy\n* Limitation of therapeutic effort or goals-of-care decisions at admission or during the observation period\n* Inability to perform hemodynamic or perfusion assessment\n* Extracorporeal membrane oxygenation (ECMO)\n* Refusal to participate in the study",{"count":114,"type":21},128,"Acute kidney injury (AKI) is common in critically ill patients and is frequently associated with fluid overload, which can worsen clinical outcomes. Continuous renal replacement therapy (CRRT) allows fluid removal through net ultrafiltration (UFNET), but some patients develop hemodynamic instability or signs of poor tissue perfusion during this process.\n\nThe purpose of this prospective observational study is to evaluate tolerance to net ultrafiltration in critically ill patients with AKI receiving CRRT. The study will assess clinical, hemodynamic, ultrasound, perfusion, and biochemical parameters before and during fluid removal to identify factors associated with ultrafiltration intolerance.\n\nThe investigators hypothesize that alterations in hemodynamic, perfusion, and congestion-related parameters can identify patients at increased risk of ultrafiltration intolerance before the development of overt hypotension. The results may help improve individualized fluid removal strategies and optimize the safety of CRRT in critically ill patients.",[117,118,119,120,121],"Acute Kidney Injury","Fluid Overload","Fluid Overload in Dialysis Patients","Critical Illness","Renal Replacement Therapy for Acute Kidney Injury in ICU",[123,124,125,126,127,118,128,129],"Net Ultrafiltration","Continuous Renal Replacement Therapy","Fluid Removal","Ultrafiltration Intolerance","Tissue Hypoperfusion","VExUS","Point-of-Care Ultrasound","2026-07-05",{"date":132,"type":36},"2026-07-08",{"date":134,"type":36},"2026-07-06",{"date":136,"type":21},"2027-12-01",{"name":138,"class":75},"Hospital Las Higueras",10,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":55,"phases":151,"briefSummary":152,"conditions":153,"keywords":156,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":76},"100643347","photodynamic-therapy-as-an-adjunct-in-periodontal-treatment-100643347","NCT07633405","Photodynamic Therapy as an Adjunct in Periodontal Treatment","Clinical Evaluation of Photodynamic Therapy as an Adjunct to Scaling and Root Planing in the Treatment of Periodontal Disease: A Split-Mouth Randomized Controlled Clinical Trial","PDT-PERIO","Inclusion Criteria:\n\n* Adults aged 18 to 65 years.\n* Diagnosis of Stage I, II, III, or IV periodontitis according to the 2018 World Workshop Classification.\n* Presence of at least two hemiarches with periodontal pockets ≥5 mm suitable for a split-mouth design.\n* Systemically healthy individuals.\n* No periodontal treatment received within the previous 6 months.\n* No use of antibiotics, anti-inflammatory drugs, or antiseptic mouth rinses within the previous 3 months.\n* Ability and willingness to provide written informed consent and attend follow-up visits.\n\nExclusion Criteria:\n\n* Uncontrolled systemic diseases that may affect healing or immune response.\n* Use of antibiotics, corticosteroids, or immunosuppressive medications within the previous 3 months.\n* Active smokers consuming more than 10 cigarettes per day.\n* Pregnant or breastfeeding women.\n* Presence of dental implants, defective restorations, or teeth with Grade III mobility in the selected study sites.\n* Known allergy to toluidine blue O or any component of the photosensitizer.\n* Individuals unable or unwilling to attend the 30-day follow-up visit.","65 Years",{"count":150,"type":21},30,[57],"This study aims to evaluate the clinical effectiveness of antimicrobial photodynamic therapy (aPDT) as an adjunct to scaling and root planing (SRP) in the treatment of periodontitis. A split-mouth design will be used, in which one hemiarch receives conventional SRP and the contralateral hemiarch receives SRP combined with aPDT. Clinical periodontal parameters, including probing pocket depth (PPD), clinical attachment level (CAL), bleeding on probing (BOP), plaque index (PI), and gingival index (GI), will be assessed at baseline and 30 days after treatment. The study seeks to determine whether adjunctive aPDT improves periodontal outcomes compared with conventional non-surgical periodontal therapy alone.",[154,155],"Periodontitis","Periodontal Disease",[154,155,157,158,159,160,161,162,163],"Antimicrobial Photodynamic Therapy","Photodynamic Therapy","aPDT","SRP","Clinical attachment level","Low level Laser therapy","Gingival Index","2026-06-02",{"date":166,"type":36},"2026-06-08",{"date":168,"type":21},"2026-07-28",{"date":170,"type":21},"2026-09-27",{"name":172,"class":75},"Universidad Catolica Santiago de Guayaquil",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":55,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":201},"100581770","effect-of-continuous-prolonged-prone-position-versus-intermittent-daily-prone-position-in-ards-100581770","NCT06854627","Effect of Continuous Prolonged Prone Position Versus Intermittent Daily Prone Position in ARDS","Effect of Continuous Prolonged Prone Position Versus Intermittent Daily Prone Position on Mortality in ARDS Patients: A Multicenter Randomized Controlled Trial","ePRONE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Endotracheal intubation and mechanical ventilation for less than 72 hours\n* Moderate-severe ARDS defined as:\n\n  1. Within 1 week of a known clinical insult or new or worsening respiratory symptoms\n  2. Bilateral infiltrates not fully explained by effusions, lobar\u002Flung collapse, or nodules\n  3. Respiratory failure not fully explained by cardiac failure or fluid overload\n  4. PaO2\u002FFiO2 \\\u003C 150 mmHg in supine position\n* Prone positioning has been indicated by the attending physician, OR has already been initiated within the last 16 hours\n\nExclusion Criteria:\n\n* Contraindications for prone positioning such as intracranial pressure \\> 20 mmHg, massive hemoptysis, recent tracheal surgery or sternotomy or abdominal surgery with an open wound, recent facial trauma or facial surgery, unstable spine, femur, or pelvic fractures, or a single anterior chest tube with air leaks\n* Patient on extracorporeal membrane oxygenation (ECMO) before randomization\n* Chronic respiratory failure requiring oxygen therapy or non-invasive ventilation (NIV)\n* Known pregnancy\n* Anticipating withdrawal of life support or shift to palliative care",{"count":182,"type":21},780,[57],"Prone position (placing the patient on his abdomen) has been shown to be an effective intervention to decrease mortality in adults connected to mechanical ventilation for moderate to severe Acute Respiratory Distress Syndrome (ARDS). Patients may require one or more sessions of prone position. However, the optimal duration of prone sessions is unknown. The goal of this clinical trial is to learn if applying prone position in prolonged sessions (\\> 48 hours - prolonged prone position) is more effective than applying it in daily sessions (16 to 24 hours - intermittent prone position). The trial will also learn about the safety of prolonged prone position compared to intermittent prone position. The main questions it aims to answer are:\n\n* Does prolonged prone position increase survival compared to intermittent prone position in participants with moderate to severe ARDS ?\n* How does prolonged prone position compare to intermittent prone position in terms of medical problems associated to prone position ?\n\nResearchers will compare prolonged versus intermittent prone position to see which approach is better to treat moderate to severe ARDS.\n\nParticipants will:\n\n* Receive prone position either in prolonged (\\> 48 hours) or daily (16 to 24 hours) sessions during the first 7 days\n* Be followed for up to 90 days to assess their clinical evolution",[186],"Acute Respiratory Distress Syndrome",[188,189,190,191],"ACUTE RESPIRATORY DISTRESS SYNDROME","RESPIRATORY FAILURE","PRONE POSITION","MECHANICAL VENTILATION","2026-05-14",{"date":194,"type":36},"2026-05-18",{"date":196,"type":36},"2025-04-07",{"date":198,"type":21},"2028-01",{"name":200,"class":75},"Pontificia Universidad Catolica de Chile",38,{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":55,"phases":212,"briefSummary":213,"conditions":214,"keywords":217,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":76},"100630208","reduced-time-interval-for-implant-placement-after-extraction-socket-preservation-using-the-vega-plus-implants-100630208","NCT07484685","Reduced Time Interval for Implant Placement After Extraction Socket Preservation Using the Vega Plus Implants","Effect of Reducing the Time Interval for Implant Placement After Extraction Socket Preservation Using the Vega Plus Implant System (Klockner): A Randomized Controlled Clinical Trial","RIP-VEGA","Inclusion Criteria:\n\n* Age: ≥ 18 years.\n* Good general health.\n* Need of extraction of incisors, canines or premolars due to carious lesion, endodontic complication, root fracture or prosthetic reason.\n* Presence of three intact socket walls after tooth extraction with a defect of 50% or more of the buccal wall.\n* Need of single-tooth implant treatment, with presence of adjacent teeth and opposing occluding teeth (for measurement stent indexing).\n* Enough available bone assessed on CBCT to place implants with 3.6 mm diameter and 10 mm in length.\n* Periodontal health in intact or reduced periodontium.\n* Full-mouth plaque and bleeding scores \\\u003C 20%.\n* Able and willing to follow study procedures and instructions.\n\nExclusion Criteria:\n\n* \\\u003C 18 years.\n* Compromised health. Existence of any systemic condition such as uncontrolled diabetes mellitus, cancer, HIV, disorders that compromise wound healing, chronic high dose steroid therapy, intravenous and oral bisphosphonate therapy, bone metabolic diseases, history of irradiation of the head and neck area, or any other immunosuppressive therapy that would contraindicate oral surgical treatment.\n* Absence of any adjacent teeth or the opposing occluding teeth.\n* The hopeless tooth is a molar.",{"count":211,"type":21},40,[57],"This randomized controlled clinical trial aims to evaluate whether reducing the healing interval for implant placement after extraction socket preservation improves clinical and radiographic outcomes compared with the conventional waiting period. Participants requiring single-tooth extraction and implant therapy will be randomly assigned to implant placement either 4 months or 6 months after ridge preservation using the Vega Plus implant system (Klockner).\n\nClinical and radiographic assessments will be performed at baseline and during follow-up visits. The primary outcome will be the mean change in horizontal alveolar ridge width measured using cone-beam computed tomography (CBCT). Secondary outcomes will include vertical bone height changes measured on CBCT, implant stability measured using resonance frequency analysis (ISQ values), marginal bone level changes assessed on standardized periapical radiographs, and postoperative pain assessed using the Visual Analog Scale (VAS).\n\nThe results of this study may contribute to optimizing treatment timing and improving efficiency in implant dentistry while maintaining favorable clinical outcomes.",[215,216],"Alveolar Bone Loss","Tooth Extraction",[218,219,220,221,222,223],"Dental implant","Tooth extraction","Alveolar ridge preservation","Guided Bone Regeneration","Bone regeneration","Dental Implant Placement","2026-04-27",{"date":226,"type":36},"2026-05-01",{"date":228,"type":36},"2026-02-28",{"date":230,"type":21},"2027-02-27",{"name":172,"class":75},{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":16,"sex":17,"minAge":239,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":55,"phases":242,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":256},"100636357","roots-for-life-project-strengthening-mental-health-in-school-communities-100636357","NCT07564635","Roots for Life Project: Strengthening Mental Health in School Communities","Pilot Study of a Mental Health Literacy-Based Intervention for Parents and Teachers to Improve the Mental Health of Children in 3rd to 5th Grade in Chile and Ecuador","Inclusion Criteria:\n\nChildren Participants:\n\n* Child is enrolled in 3rd, 4th, or 5th grade of primary school\n* Child is under 12 years of age\n* Child's parent or legal guardian has provided written informed consent\n* Child attends a participating public or subsidized school in Valparaíso, Achao, Curaco de Vélez (Chile), or Daule (Ecuador)\n\nTeachers:\n\n* Works as a teacher in a participating school\n* Teaches students in first or second cycle of primary education (grades 1-6)\n* Voluntarily agrees to participate in the study\n\nParents\u002FCaregivers:\n\n* Is the parent or caregiver of a child under 12 years of age\n* Child is enrolled in 3rd, 4th, or 5th grade of primary school\n* Voluntarily agrees to participate in the study\n\nExclusion Criteria:\n\nChildren Participants:\n\n\\- Child has sensory problems or physical disabilities that prevent completion of surveys\n\nTeachers:\n\n* Works as educational assistant or in administrative functions only\n* Voluntarily declines to participate in the study\n\nParents\u002FCaregivers:\n\n* Child has sensory problems or physical disabilities that prevent completion of surveys\n* Voluntarily declines to participate in the study","5 Years",{"count":241,"type":21},200,[57],"This pilot study, titled \"Roots for Life Project: Strengthening Mental Health in School Communities\", aims to evaluate the feasibility and preliminary effectiveness of a mental health literacy (MHL) intervention for teachers and parents to improve the mental health of children aged 8-11 years (3rd to 5th grade) in primary schools located in socially vulnerable areas of Chile and Ecuador.\n\nChild mental health problems represent a major burden worldwide, with high prevalence and a treatment gap exceeding 70% in Latin America. Schools and families play a key role in early detection, yet both often lack the necessary knowledge and confidence to identify mental health difficulties or seek appropriate help. Increasing mental health literacy-defined as knowledge and beliefs that support recognition, management, and prevention of mental health problems-has proven to enhance early help-seeking, reduce stigma, and promote wellbeing.\n\nThe project builds upon the prior Chilean FONIS Project SA21I0143, which tested a teacher-focused MHL program and demonstrated improvements in teachers' knowledge, reduced depressive symptoms, and lower burnout levels. The current study extends this work by (1) adding a parent-focused component, (2) evaluating outcomes in children, and (3) implementing the program in two countries to assess cross-cultural feasibility.\n\nThis quasi-experimental study will include seven primary schools-five in Chile (Valparaíso, Achao, Curaco de Vélez) and two in Ecuador (Daule). Schools will be randomly assigned within each locality to either intervention or control conditions. Approximately 230 children, their parents\u002Fguardians, and teachers will participate. Assessments will be conducted before and after the intervention using validated instruments.\n\nThe teacher program consists of six 2-hour participatory workshops covering topics such as self-care, child development, anxiety and depression, suicide prevention, behavioral disorders, autism, and child maltreatment. The parent program includes three 90-minute educational sessions addressing stigma, social support, healthy development, and emotional containment. Both components emphasize experiential learning and culturally adapted materials.\n\nPrimary outcome:\n\nMental health literacy among parents and teachers (MHL Scale).\n\nSecondary outcomes:\n\nPsychological wellbeing of adults (GHQ-12).\n\nChronic stress levels in children (cortisol in fingernails).\n\nAdverse childhood experiences (ACE questionnaire).\n\nImplementation indicators (acceptability, satisfaction, barriers, facilitators).\n\nQuantitative analyses will compare pre- and post-intervention outcomes and calculate effect sizes. Mediation and moderation models will explore relationships among child, family, and school-level variables. Qualitative data from focus groups with parents and teachers will complement these findings to evaluate feasibility and contextual adaptations.",[245],"Mental Health Literacy",[245],"2026-04-26",{"date":249,"type":36},"2026-05-04",{"date":251,"type":36},"2025-03-01",{"date":253,"type":21},"2026-07-31",{"name":255,"class":75},"Universidad de Valparaiso",3,{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":265,"minAge":18,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":268,"conditions":269,"keywords":275,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":295},"100598171","organ-dysfunction-score-for-obstetric-patients-100598171","NCT07068022","Organ Dysfunction Score for Obstetric Patients","Development and Validation of an Obstetric Organ Dysfunction Score to Predict Mortality in Intensive Care Unit: A Multicenter, Prospective, Cohort Study","SOFA-OBS","Inclusion Criteria:\n\nAll of the following=\n\n* Pregnant (at any gestational age) or post-partum patients (at ≤3 days postpartum)\n* ≥ 18 years old\n* Requiring admission to ICU for any reason\n* Staying in the ICU for ≥ 24h\n* Giving her consent to participate. Patients will be recruited consecutively until reaching the sample size.\n\nExclusion Criteria:\n\nAny of the following=\n\n* Patients \\\u003C18 years old\n* Non-pregnant patients\n* ≥ 4 days postpartum\n* Patients or surrogates not giving consent to participate\n* ICU-LOS \\\u003C 24 h","FEMALE",{"count":267,"type":21},130,"The goal of this observational study is to develop and evaluate an organ dysfunction score adapted to pregnancy and early puerperium (SOFA-OBS) that also incorporates a non-invasive tool to evaluate respiratory function (pulse oximeter).\n\nThe main question it aims to answer is: Does an organ dysfunction score adapted to pregnant and postpartum patients have a higher capacity to predict mortality than a non-adjusted organ dysfunction score? Participants: Patients requiring ICU (Intensive Care Units) admission, who are either pregnant or postpartum (up to 3 days after giving birth). The investigators aimed to include 130 participants.\n\nThe investigators will only collect participants' data and laboratory results that ICU doctor usually need for clinical practice. No additional interventions are required. Moreover, the investigators will evaluate if measuring participants' oxygenation through a non-invasive tool (pulse oximeter) is equally effective as measuring oxygenation by an arterial puncture.\n\nBackground: When managing severely ill patients in ICU, the investigators often use what it is called scores. Scores refer to a numerical value assigned to a patient's condition, which often predict outcome. The Sequential Organ Failure Assessment (SOFA) score is a scoring system that assess severity of organ dysfunction (in liver, kidney, blood pressure, respiratory, neurologic and platelets). It also identifies patients with severe infections (sepsis) and patients with bad outcomes.\n\nPatients undergoing pregnancy or early postpartum develop physiological changes, such us a decrease in creatinine (a laboratory test measuring kidney function) and a decrease in blood pressure during the second trimester. These changes are not considered by the SOFA score. Actually, there is not an organ dysfunction score adapted to pregnant\u002Fpostpartum patients to be used in the ICU. Moreover, a blood sample taken by arterial puncture is required to evaluate respiratory function by the SOFA score, which is a painful procedure. Instead, the investigators could evaluate respiratory function using a pulse oximeter, which measures peripheral oxygen saturation without needing an arterial puncture.\n\nPotential benefits: A SOFA-OBS would hopefully become a more precise tool than general SOFA to evaluate organ dysfunction and to predict outcome among these patients. It would also help to detect sepsis earlier and treat it promptly, which might help reducing its mortality.",[270,271,272,273,274],"Pregnancy","Postpartum","Organ Dysfunction","Critical Care, Intensive Care","Sepsis",[276,270,271,277,278,279,280,281,282,283,274,284,285],"Sequential Organ Failure Assessment score","Critical care","Intensive Care Unit","Creatinine","Peripheral oxygen saturation","Hypotension","Maternal mortality","Mortality","Septic shock","Multicenter study","2026-04-22",{"date":288,"type":36},"2026-04-28",{"date":290,"type":36},"2025-10-06",{"date":292,"type":21},"2027-02-28",{"name":294,"class":75},"Daniela Vasquez",18,{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":55,"phases":306,"briefSummary":308,"conditions":309,"keywords":313,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":327},"100421926","phase-3-low-dose-colchicine-in-patients-with-peripheral-artery-disease-to-address-residual-vascular-risk-100421926","NCT04774159","Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk","Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk: A Randomized Trial","LEADER-PAD","Inclusion criteria:\n\n1. Age \\> 18 years\n2. Symptomatic atherosclerotic LE PAD fulfilling at least one of the following:\n\n   a. Intermittent claudication with ankle\u002Farm blood pressure ratio\\* (ABI ≤ 0.90) or artery stenosis ≥ 50% plus one of i. \\>1 vascular bed affected by atherosclerosis ii. Diabetes iii. Heart failure iv. Chronic kidney disease (eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m2)\n\n   b. Rest pain (mostly in foot) OR necrosis of limb OR gangrene of limb (corresponding to either Fontaine stages 3 or 4 OR Rutherford Classification categories 4 to 6). All must have an ankle\u002Farm blood pressure ratio\\* (ABI ≤ 0.90) OR artery stenosis ≥ 50%.\n\n   \\* In cases of incompressible ankle arteries, the presence of toe pressure ≤ 60 mm Hg or toe-brachial index ≤ 0.70 is acceptable\n\n   c. Revascularization defined as limb bypass surgery or endovascular revascularization procedures (irrespective of the specific device used), including percutaneous transluminal angioplasty\u002Fstent of iliac or infra-inguinal arteries or extra-anatomical bypass surgery\n\n   d. Leg or foot amputation for arterial vascular indications\n3. Written or verbal informed consent from the patient\n\nExclusion Criteria:\n\n1. Contraindication to colchicine\n2. Long term requirement for colchicine for another clinical indication\n3. Active diarrhoea\n4. eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n5. Cirrhosis or severe chronic liver disease\n6. Woman who is pregnant, or breast-feeding or of child-bearing potential not protected by reliable contraception or is planning conception during the study\n7. Current or planned long term use of cyclosporine, verapamil, HIV protease inhibitors, azole antifungals, or macrolide antibiotics (with the exception of azithromycin)\n8. Patients who are deemed unlikely to return for follow-up\n9. Patients with life expectancy \\\u003C 1 year",{"count":305,"type":21},6150,[307],"PHASE3","The Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with symptomatic peripheral artery disease.",[310,311,312],"Peripheral Arterial Disease","Atherosclerosis of Extremities","Inflammation",[314,315,316,317,283],"Acute limb ischemia","Myocardial Infarction","Stroke","Cardiovascular death","2026-03-20",{"date":320,"type":36},"2026-03-24",{"date":322,"type":36},"2021-05-06",{"date":324,"type":21},"2029-12",{"name":326,"class":75},"Population Health Research Institute",70,{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":16,"sex":17,"minAge":336,"maxAge":337,"enrollmentInfo":338,"targetDuration":239,"studyType":22,"phases":4,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":76},"100630284","genesis-project-generating-evidence-on-the-needs-of-ecuadorian-adolescents-100630284","NCT07485673","GENESIS Project: Generating Evidence on the Needs of Ecuadorian Adolescents","Generating Evidence on the Needs of Ecuadorian Adolescents","GENESIS","Inclusion Criteria:\n\n* be between 14 and 19 years old\n\nExclusion Criteria:\n\n* have any disorder or treatment that contraindicated physical activity or that demanded special assistance\n* be under some pharmacological treatment;\n* not be authorized by parents, caregivers, or legal guardians to participate in the research project\n* do not agree to take part in the research project\n* for volunteering retirement.","14 Years","19 Years",{"count":339,"type":21},1450,"Background: Adolescence is a period of intensified emotional responses and occurs when mental health disorders commonly develop since adolescents are learning how to deal with powerful emotions. Globally, 15% of adolescents experience a mental disorder like depression or anxiety. However, adolescent mental health goes beyond mental disorders. It is state of mental well-being that allows individuals to deal with stressors, recognize their abilities, develop their activities well, and participate in society, providing a holistic approach that highlights the interplay between psychological well-being and other aspects of life. Given this perspective, a Lifestyle Medicine (LM) approach based on a multi-component framework is needed for assessing adolescents' mental health. This study aims to evaluate adolescents' (aged 14-19) mental health, identify and mitigate the risks of developing any mental health disorder as well as formulate comprehensive interventions to promote and increase their emotional wellbeing. Methods: Cross-sectional and longitudinal studies will be performed. Adolescents from Quito, Ecuador will be recruited using a simple random sampling technique. The minimum sample size is 385; however, to increase the precision of the estimates, a target sample of approximately 1000 participants will be established. Main outcome measure will be mental health using social determinants of health and lifestyle medicine factors. Conclusion: This research project will evaluate adolescents' mental health through a holistic and multiapproach evaluation and interrelate social determinants of health and lifestyle medicine variables to propose and design multidisciplinary strategies and interventions to prevent and mitigate mental health outcomes in adolescents. Additionally, the results will be useful in informing public health authorities to evaluate or modify current policies",[342,343,344],"Adolescent Development","Mental Health Issue","Lifestyle Factors","2026-03-16",{"date":318,"type":36},{"date":348,"type":36},"2025-09-04",{"date":350,"type":21},"2030-08",{"name":74,"class":75},{"id":353,"slug":354,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":361,"conditions":362,"keywords":367,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":384},"100613110","epidemiology-and-processes-of-care-for-renal-replacement-therapy-in-acute-kidney-injury-in-latin-america-100613110","NCT07262320","Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America","LATAM-AKID","Inclusion Criteria:\n\n* Adult patient (≥18) admitted to the ICU\n* First ICU admission during current hospitalization\n* Diagnosis of acute kidney injury stage 3 according to KDIGO guidelines\n* RRT initiated no earlier than 3 days before or no later than 7 days after ICU admission\n\nExclusion Criteria:\n\n* Transfer from outside hospital with ongoing RRT\n* RRT exposure of less than 2 days (if CRRT or PD was provided) or less than 2 HD\u002FSLED sessions\n* Kidney failure (ESRD) patients on maintenance dialysis\n* Kidney transplant recipients\n* Previous or new diagnosis of glomerulonephritis",{"count":360,"type":21},1000,"This is an international, multicenter, observational study aimed at investigating acute kidney injury requiring renal replacement therapy (AKI-RRT) in Latin American countries. The main questions this study aims to answer are:\n\n* What is the epidemiology, outcomes, and processes of care for patients with AKI-RRT in Latin America?\n* How do outcomes differ across different countries in Latin America?\n* What factors (demographics, clinical, socioeconomic) influence outcomes in patients with AKI-RRT in Latin America?\n\nThe main aims of this study are to:\n\n* Establish a comprehensive database containing clinical, laboratory, treatment, process, and outcome data of patients with AKI-RRT in Latin America\n* Describe current epidemiology of AKI-RRT in Latin America\n* Compare processes of care and outcomes across different countries in Latin America\n* Provide data resources to facilitate and promote clinical research in AKI-RRT",[363,364,121,117,365,366],"Dialysis","Critically Ill Acute Kidney Injury","Renal Replacement Therapy","AKI",[366,368,369,370,371,372,373,374],"ICU","RRT","Latin America","acute kidney injury","renal replacement therapy","intensive care unit","dialysis","2026-03-11",{"date":377,"type":36},"2026-03-12",{"date":379,"type":36},"2026-03-01",{"date":381,"type":21},"2027-06-30",{"name":383,"class":75},"University of Alabama at Birmingham",15,{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":392,"enrollmentInfo":393,"targetDuration":4,"studyType":55,"phases":395,"briefSummary":396,"conditions":397,"keywords":399,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":408,"locationsCount":76},"100615234","effects-of-respiratory-muscle-training-in-post-bariatric-surgery-patients-100615234","NCT07289958","Effects of Respiratory Muscle Training in Post-bariatric Surgery Patients","Effects of Respiratory Muscle Training on Cardiovascular, Respiratory, Metabolic and Physical Exercise Capacity Parameters Related to Obesity in Post-bariatric Surgery Patients","Inclusion Criteria:\n\n* Patients diagnosed with obesity within 1 month of bariatric surgery\n* Both sexes\n* Ages 18 to 60\n\nExclusion Criteria:\n\n* Patients with respiratory conditions that contraindicate physical exercise\n* Patients with diagnosed heart disease\n* Patients with psychiatric conditions\n* Patients with osteoarticular conditions that make physical exercise difficult","60 Years",{"count":394,"type":21},52,[57],"Obesity is a health condition caused by excessive accumulation of body fat. This condition is linked to the development of chronic diseases and also places increased stress on the respiratory system, leading to respiratory disorders, exacerbation of preexisting respiratory conditions, and a decline in physical capacity and exercise tolerance.\n\nRespiratory muscle training has been shown to have beneficial effects on respiratory function in these patients, although the effects this strategy has on other metabolic and physiological aspects related to exercise and obesity that are affected remain unclear.",[398],"Bariatric Surgery",[398,400,401],"Inspiratory muscle training","Therapeutic exercise","2026-02-13",{"date":404,"type":36},"2026-02-18",{"date":406,"type":36},"2026-01-05",{"date":381,"type":21},{"name":409,"class":75},"University Ramon Llull",{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":55,"phases":419,"briefSummary":420,"conditions":421,"keywords":424,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":433,"locationsCount":435},"100624231","safety-and-efficacy-of-a-novel-spydrblade-flexible-bipolar-in-poem-100624231","NCT07406945","Safety and Efficacy of a Novel SpydrBlade Flexible Bipolar in POEM","Safety and Efficacy of the Novel SpydrBlade Flex With Radiofrequency and Microwave Ablation Flexible Bipolar for Per-Oral Endoscopic Myotomy in Patients With Achalasia: A Multicenter Prospective Study","Inclusion Criteria:\n\n* Patients with 18 years of age or older.\n* Patients referred to the participating center with a clinical indication for POEM. This includes conditions such as: achalasia, native or failed Heller myotomy, balloon dilation, and EGJ outflow obstruction.\n* Patients who provide informed consent.\n\nExclusion Criteria:\n\n* Patients who have contraindications for EGD.\n* Patients with an Eckardt score \\\u003C 3 before POEM.\n* Positive diagnosis of Chagas disease.\n* Patients unable to withstand general anesthesia.",{"count":418,"type":21},73,[57],"Achalasia is an idiopathic motility disorder, primarily identified by the absence of esophageal peristalsis and the inability of the lower esophageal sphincter (LES) to relax properly. Although it is usually misdiagnosed and treated as gastroesophageal reflux disease (GERD), the main symptom is progressive dysphagia, accompanied by additional symptoms like nocturnal cough, heartburn, weight loss, regurgitation of undigested food and aspiration.\n\nThe severity of achalasia and the effectiveness of treatments are commonly assessed using the Eckardt Symptom Score (ESS), which evaluates symptoms like weight loss, regurgitation, dysphagia, and retrosternal pain.\n\nDiagnosis of achalasia is often delayed, affecting up to 50% of patients. It typically involves a combination of diagnostic tools, such as time barium esophagram (TBE) study, which assesses the movement and clearance of barium in the esophagus; esophagogastroduodenoscopy (EGD), which allows visual examination of the esophagus, stomach, and duodenum; and high-resolution esophageal manometry (HREM), considered the gold standard for achalasia. HREM can also help stratify the condition into different types, influencing treatment choices. Furthermore, the endoluminal functional lumen imaging probe (Endoflip, Crospon Corp, Dangan Galaway, Ireland), which measures baseline parameters of LES, aiding in both diagnosis and treatment evolution.\n\nWhile there is no cure for achalasia, treatments aim to reduce LES pressure. The include pharmacological treatments, such as calcium channel blockers or nitrates; endoscopic treatment, including injection of botulinum toxin in the LES, pneumatic dilation, or per-oral endoscopic myotomy (POEM); and surgical therapies (laparoscopic Heller myotomy). POEM has emerged as a first-line treatment for achalasia due to its minimally invasive nature and high success rates (80%-90%). This technique involves creating a submucosal tunnel and performing myotomy, and it can be performed anteriorly (at 2 o'clock) or posteriorly (at 5 o'clock).\n\nThe choice between anterior and posterior approaches to POEM often depends on the endoscopist's experience and preference. While current data is inconclusive regarding the superiority of either approach, some suggest that the posterior approach might be technically easier due to procedural characteristics (i.e., alignment between endoscopic accessories and mucosal incision). The introduction to novel technologies with smaller diameters can improve this minimally invasive approach making the procedure more efficient and safer for patients with achalasia. Thus, we aim to evaluate the safety and effectiveness of a novel radiofrequency and microwave ablation flexible bipolar (SpydrBlade Flex, CREO Medical, UK) for per-oral endoscopic myotomy in patients with achalasia.",[422,423],"Achalasia","EGJ Outflow Obstruction",[425,426],"Novel Flexible Bipolar","POEM","2026-02-06",{"date":429,"type":36},"2026-02-12",{"date":431,"type":36},"2024-11-01",{"date":72,"type":21},{"name":434,"class":75},"Chinese University of Hong Kong",2,{"id":437,"slug":438,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":16,"sex":17,"minAge":444,"maxAge":4,"enrollmentInfo":445,"targetDuration":447,"studyType":22,"phases":4,"briefSummary":448,"conditions":449,"keywords":451,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":470},"100612766","practice-based-evidence-in-psychotherapy-a-multicentric-study-from-ecuador-100612766","NCT07257848","Practice-Based Evidence in Psychotherapy: A Multicentric Study From Ecuador","Practice-Based Evidence in Ecuador: Routine Monitoring of Outcomes and Change in Psychotherapy for Common Mental Health Problems","CLIP_Ecuador","Clients\n\nInclusion Criteria:\n\n* Be 11 years of age or older.\n* Have sufficient ability to communicate in Spanish.\n* Undergo psychological treatment at one of the mental health services included in the project.\n\nExclusion Criteria:\n\n* Present substantial cognitive deficits that do not allow the development of the evaluation.\n\nTherapists\n\nInclusion Criteria:\n\n* Therapist providing psychological treatment at one of the mental health services included in the project.\n\nSupervisors\n\nInclusion Criteria:\n\n* Provide clinical supervision to therapists delivering treatment at any of the project's affiliated mental health services.","11 Years",{"count":446,"type":21},340,"12 Months","The goal of this observational study is to learn about the progress and outcomes of clients receiving psychotherapy for common mental health problems in Ecuador. The main questions it aims to answer are:\n\n* How much do clients' psychological distress typically change during the course of their psychotherapy?\n* What factors are associated with outcomes in real-world mental health services in Ecuador?\n\nThis study involves clients who are about to start psychotherapy at one of the participating mental health clinics in Ecuador. Participants will continue their regular psychotherapy sessions as usual. The only addition is that before their sessions, they will be asked to complete questionnaires about their general well-being. This routine check-in process will continue throughout their time in therapy. Contextual information will be collected before starting treatment, and satisfaction with the treatment and any contextual changes will be collected after treatment ends.",[450],"Psychological Distress",[452,453,454,455,456,457,458,370,459,460],"practice-based evidence","routine outcome monitoring","psychotherapy","practice-oriented research","change","outcome","psychological distress","Practice Research Network","Consorcio Latinoamericano de Investigación en Psicoterapia","2025-11-25",{"date":463,"type":36},"2025-12-02",{"date":465,"type":36},"2025-02-21",{"date":467,"type":21},"2028-08-31",{"name":469,"class":75},"Universidad de las Americas - Quito",11,{"id":472,"slug":473,"hasResults":11,"nctId":474,"briefTitle":475,"officialTitle":475,"acronym":476,"eligibilityCriteria":477,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":478,"targetDuration":480,"studyType":22,"phases":4,"briefSummary":481,"conditions":482,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":493},"100272903","computerized-registry-of-patients-with-venous-thromboembolism-riete-100272903","NCT02832245","Computerized Registry of Patients With Venous Thromboembolism (RIETE)","RIETE","Inclusion Criteria:\n\n* Confirmed VTE (acute deep-vein thrombosis, pulmonary embolism and\u002For superficial venous thrombosis) by objective tests.\n* Informed consent to the participation in the study, according to the requirements of the ethics committee within each hospital.\n\nExclusion Criteria:\n\n* Participation in a therapeutic clinical trial with an unknown drug.\n* Inability to the 3 month follow-up",{"count":479,"type":21},120000,"3 Years","The Computerized Registry of Patients with Venous Thromboembolism (RIETE) is a multidisciplinary Project initiated in march 2001 and consisting in obtaining an extensive data registry of consecutive patients with venous thromboembolism.\n\nThe main objective is to provide information on the Internet to help physicians to improve their knowledge on the natural history of thromboembolic disease, particularly in those subgroups of patients who are usually not recruited in randomized clinical trials (pregnant women, elderly patients, disseminated cancer, severe renal insufficiency, patients with contraindications to anticoagulation therapy, extreme body weight, etc), with the purpose of decreasing mortality, frequency of thromboembolic recurrences as well as bleeding complications and arterial events.\n\nAs an additional objective RIETE is also aimed to create predictive scores that help physicians to better identify patients with high risk of presenting some of these complications.\n\nThe primary parameters recorded by the registry comprise details of each patient's clinical status, including any coexisting or underlying conditions, and the type, dose, duration and outcome (during the first 3 months of therapy) of antithrombotic treatment. Study endpoints are clinically recognized (and objectively confirmed) recurrences of VTE, major and minor bleeding complications, and death.",[483],"Venous Thromboembolism","2025-09-23",{"date":486,"type":36},"2025-09-24",{"date":488,"type":4},"2001-03",{"date":490,"type":21},"2027-12",{"name":492,"class":75},"Manuel Monreal",257,{"id":495,"slug":496,"hasResults":11,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":500,"eligibilityCriteria":501,"healthyVolunteers":16,"sex":265,"minAge":18,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":55,"phases":504,"briefSummary":505,"conditions":506,"keywords":512,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":523},"100421367","sflt1plgf-and-planned-delivery-to-prevent-preeclampsia-at-term-100421367","NCT04766866","sFlt1\u002FPlGF and Planned Delivery to Prevent Preeclampsia at Term.","Protocol of the PE37 Study: A Multicenter Randomized Trial of Screening With sFlt1\u002FPlGF and Planned Delivery to Prevent Preeclampsia at Term","PE37","Inclusion Criteria:\n\n* Nulliparous women\n* Singleton pregnancies\n* \\>18 years old\n* 35.0-36.6 weeks of gestation\n* Maternal written consent form\n\nExclusion Criteria:\n\n* Fetuses\u002Fneonates with major malformations or genetic anomalies that could modify the timing of delivery or has an impact on obstetric outcome\n* Suspected fetal growth restriction (estimated fetal weight \\\u003C3 centile or between the 3rd and 10th centile together with abnormal Doppler in the mean uterine artery Doppler pulsatility index, or in umbilical artery pulsatility index or in the middle cerebral artery or in the cerebral umbilical index (CPR))\n* Participation in another interventional study that could modify the timing of delivery.",{"count":503,"type":21},9132,[57],"* Preeclampsia (PE) affects \\~5% of pregnancies. Although improved obstetrical care has significantly diminished associated maternal mortality, PE remains a leading cause of maternal morbidity and mortality in the world.\n* Term PE accounts for 70% of all PE and a large proportion of maternal-fetal morbidity related with this condition. Prediction and prevention of term PE remains unsolved.\n* Previously proposed approaches are based on combined screening and\u002For prophylactic drugs, but these policies are unlikely to be implementable in many world settings.\n* Recent evidence shows that sFlt1-PlGF ratio at 35-37w predicts term PE with 80% detection rate.\n* Likewise, recent studies demonstrate that induction of labor (IOL) from 37w is safe.\n* The investigators hypothesize that a single-step universal screening for term PE based on sFlt1\u002FPlGF ratio at 35-37w followed by IOL from 37w would reduce the prevalence of term PE without increasing cesarean section rates or adverse neonatal outcomes.\n* The investigators propose a randomized clinical trial to evaluate the impact of a screening of term PE with sFlt-1\u002FPlGF ratio in asymptomatic nulliparous women at 35-37w. Women will be assigned to revealed (sFlt-1\u002FPlGF known to clinicians) versus concealed (unknown) arms. A cutoff of \\>90th centile will be used to define high risk of PE and offer IOL from 37w.\n* If successful, the results of this trial will provide evidence to support a simple universal screening strategy reducing the prevalence of term PE, which could be applicable in most healthcare settings and have enormous implications on perinatal outcomes and public health policies worldwide.",[507,508,509,510,511],"Preeclampsia","Intrauterine Growth Restriction","Maternal Hypertension","Neonatal Outcome","Perinatal Death",[513],"Preeclampsia, angiogenic factors, perinatal death, induction of labour","2025-02-17",{"date":516,"type":36},"2025-02-19",{"date":518,"type":36},"2021-03-02",{"date":520,"type":21},"2026-12-31",{"name":522,"class":75},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",21,{"id":525,"slug":526,"hasResults":11,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":11,"sex":17,"minAge":531,"maxAge":18,"enrollmentInfo":532,"targetDuration":4,"studyType":55,"phases":534,"briefSummary":535,"conditions":536,"keywords":539,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":76},"100578642","impact-of-a-physical-activity-program-on-the-health-related-quality-of-life-in-pediatric-cancer-patients-100578642","NCT06813950","Impact of a Physical Activity Program on the Health-Related Quality of Life in Pediatric Cancer Patients","IMPACT of a PHYSICAL ACTIVITY PROGRAM on the HEALTH-RELATED QUALITY of LIFE in PEDIATRIC CANCER PATIENTS","Inclusion Criteria:\n\n* 1\\. Age range: Participants must be between 8 and 18 years old at the start of the study.\n\n  2\\. Residency: Patients residing within the city limits of Quito, Ecuador. 3. Treatment status:\n\n  • Patients are being evaluated or treated at Hospitals SOLCA and Baca Ortiz.\n  * Patients are either currently undergoing active treatment for pediatric malignancies, or\n  * Patients are in the post-treatment phase after a pediatric cancer diagnosis.\n  * The volunteer or a family member that lives with the possible participant has a cellphone so the survey can be administered and answered.\n\nExclusion Criteria:\n\n* 1\\. The presence of a malignant solid tumor which has not yet been surgically addressed.\n\n  2\\. A psychiatric diagnosis of cognitive impairment. 3. A diagnosis of osteosarcoma. 4. A history of cardiac pathology. 5. The patient is in the pediatric inpatient ward or was one month prior to the enrollment phase.\n\n  6\\. The patient is stationed at the pediatric intensive care unit. 7. The patient received high-dose chemotherapy with methotrexate greater than 1000 mg\u002Fm2\u002Fdose or cytarabine greater than 1 g\u002Fm2\u002Fdose in the last month.","8 Years",{"count":533,"type":21},80,[57],"Physical activity is essential for the health and well-being of children and adolescents. However, those living with cancer often experience reduced physical activity levels, which negatively impact their functional capacity and health-related quality of life (HRQoL). In Ecuador, data from the National Institute of Statistics and Census (2021) reveal that 20% of children engage in less than one hour of physical activity per week, highlighting the need for targeted interventions. While previous studies demonstrate that supervised exercise programs can improve physical and psychosocial health outcomes in pediatric oncology patients, no evidence exists from Ecuador to assess the effects of such programs.\n\nThis study will examine the impact of a structured physical activity program on the HRQoLof pediatric cancer patients in Quito, Ecuador. Using a case-control design, 90 participants will be randomized into two groups: an intervention group receiving a 10-week, supervised physical activity program and a control group with no exercise intervention and the programmed usual care as follow up if needed by the social worker. HRQoL surveys using a standardized instrument will be administered to all participants (those in the intervention group and those in the control group) at weeks 1, 12, and 24 to assess changes over time.\n\nThis research will address a critical public health gap by exploring how physical activity can mitigate the adverse effects of cancer treatment, improve physical and emotional health, and enhance the HRQoL in pediatric oncology patients. Findings will contribute valuable insights for integrating physical activity into pediatric oncology care in low- and middle-income countries.",[537,538],"Cancer","Pediatric Cancer",[540,541,542,543],"physical activity","Quality of life","physical activity programs","lifestyle","2025-02-07",{"date":546,"type":36},"2025-02-11",{"date":548,"type":21},"2025-02-20",{"date":550,"type":21},"2025-12",{"name":552,"class":75},"Sociedad de Lucha Contra el Cáncer",{"id":554,"slug":555,"hasResults":11,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":559,"eligibilityCriteria":560,"healthyVolunteers":11,"sex":265,"minAge":561,"maxAge":148,"enrollmentInfo":562,"targetDuration":4,"studyType":55,"phases":563,"briefSummary":564,"conditions":565,"keywords":568,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":435},"100539497","hospital-based-validation-of-the-new-elevate-screening-tool-100539497","NCT06304610","Hospital-based Validation of the New ELEVATE Screening Tool","Hospital-based Validation of the New ELEVATE Screening Tool in Belgium and Ecuador","ELEVATE-Pilot","Inclusion Criteria:\n\n* have a previous abnormal pap smear\u002Frecent diagnosis of cervical dysplasia (\\\u003C4 months) and therefore have a colposcopy appointment, or\n* a positive HPV test (\\\u003C4 months) and therefore have a colposcopy appointment, and\n* able to understand the study materials (questionnaire) and informed consent form\n\nExclusion Criteria:\n\n* women with heavy bleeding at consultation\n* women with known pregnancy at consultation\n* women who are undergoing or have completed chemotherapy in the six months prior to the enrollment, or received LEEP, cryotherapy or another treatment in the six months prior to enrollment\n* women who do not consent","30 Years",{"count":241,"type":21},[57],"ELEVATE is a six-year project, conducted by an international research alliance led by Ghent University, aiming to develop a new test and approach for cervical cancer screening in hard-to-reach populations.\n\nIn this final stage of the project, a hospital-based validation study is deployed in Belgium and Ecuador to clinically validate the new ELEVATE screening test based on self-samples and endocervical samples. The simultaneous detection of HPV DNA and the proteomic markers allows for the detection of those cervical HPV infections associated with progression towards cervical cancer.\n\nAt each study site, 100 women between 30-65 years old, with a recent abnormal pap smear result will be recruited in the colposcopy waiting room. After registration and signing the informed consent form, each woman will be asked to fill out a short self-administered questionnaire for socio-demographic information. Each woman will provide a self-sample as well as an endocervical sample before the colposcopy examination. Both samples of all 200 women (i.e. participants from Belgium and Ecuador) will be tested with the new ELEVATE screening test, using 400 ELEVATE cartridges, as well as with standard tests.\n\nBesides analyzing all samples on the new ELEVATE screening test, the following standard tests will also be performed on all samples (at Ghent University - including the shipped samples of Ecuador):\n\n* AnyplexTM II HPV HR Detection (Segeene Inc., Korea): approved comparison test\n* ELISA protein detection: only available comparison test\n\nIn order to generate HPV DNA results locally, that can be communicated to the participants in short time (versus waiting for AnyplexTM II HPV HR Detection test results after shipment to Belgium), in Ecuador the following additional standard test will be performed on the100 endocervical samples (before shipment to Belgium):\n\n• HPV DNA Mole Bioscience test\n\nConcordance between the test results of the ELEVATE screening test and standard lab tests on both type of samples will be defined, for HPV DNA as well as protein detection. Additionally, the sensitivity and specificity of the HPV DNA test and the protein test of the ELEVATE screening test will be defined, according to clinically relevant outcomes.",[566,567],"Cervical Cancer","HPV Infection",[569,570,571,572,573,574],"cervical cancer","screening","self-sampling","HPV","underscreened","new ELEVATE tool","2025-01-22",{"date":577,"type":36},"2025-01-27",{"date":579,"type":21},"2025-03",{"date":581,"type":21},"2026-12",{"name":583,"class":75},"University Hospital, Ghent",{"id":585,"slug":586,"hasResults":11,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":55,"phases":593,"briefSummary":594,"conditions":595,"keywords":596,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":76},"100566952","effectiveness-of-alveolar-bone-preservation-in-alveoli-with-infectious-process-100566952","NCT06661863","Effectiveness of Alveolar Bone Preservation in Alveoli With Infectious Process","Effectiveness of Autologous Bone and Bioactive Glass for Alveolar Preservation in Alveoli With Infectious Process","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Patients with indicated tooth extractions\n* Patients who have accepted the conditions of the study\n\nExclusion Criteria:\n\n* Pregnant patients, breastfeeding or using oral contraceptives\n* Smoking patients\n* Patients with uncontrolled systemic diseases\n* History of autoimmune disease\n* Previous traumatic extraction\n* Patients taking bisphosphonates or anticoagulants\n* Patients who are or have undergone chemotherapy and radiotherapy",{"count":592,"type":21},28,[57],"Alveolar ridge preservation (ARP) is a surgical technique that aims to minimize the degree of dimensional changes following extraction. In the healing period after extraction, the alveolar bone (AB) undergoes morphological changes during the remodeling process. The changes become evident immediately after tooth extraction, with greater resorption changes observed during the first two months, and these dimensional changes can be observed 1 year after surgery.",[215],[597,598,60,61],"Alveolar Resorption","Alveolar process","2024-10-25",{"date":601,"type":36},"2024-10-28",{"date":603,"type":21},"2024-11-15",{"date":605,"type":21},"2029-12-15",{"name":74,"class":75},{"id":608,"slug":609,"hasResults":11,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":613,"eligibilityCriteria":614,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":615,"targetDuration":4,"studyType":55,"phases":616,"briefSummary":617,"conditions":618,"keywords":620,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":629,"locationsCount":76},"100560720","efficacy-of-the-modified-free-gingival-graft-technique-100560720","NCT06580821","Efficacy of the Modified Free Gingival Graft Technique","Evaluation of the Efficacy of the Modified Free Gingival Graft Technique","FGG","Inclusion Criteria:\n\n* Patients with at least two or less localized recession in mandibular incisors\n* Cairo type 1 recession\n* Patients who have good plaque control of less than 20%\n* Patients between 18-64 years old\n\nExclusion Criteria:\n\n* Systemically compromised patients\n* Smoker patients\n* Pregnant women, breastfeeding or use of oral contraceptives\n* Patients who are taking medication that may affect healing and coagulation\n* Previous periodontal surgeries in the RG area\n* Patients with periodontal disease\n* Patients who have undergone chemotherapy and radiotherapy",{"count":150,"type":21},[57],"Gingival recessions can be defined as the exposure of the root surface after an apical migration of the gingival margin in relation to the cemento-enamel junction. Gingival recessions affect both younger and older populations. Various surveys revealed that 88% of people ≥65 years of age and 50% of people between 18 and 64 years of age have ≥1 site with gingival recession. Gingival recessions can occur due to anatomical, pathological factors or trauma and will result in a loss of attachment.",[619],"Modified Free Gingival Graft , Connective Tissue Graft",[621,622,623],"Gingival Recession","Surgical Flaps","Connective Tissue",{"date":625,"type":36},"2024-10-29",{"date":627,"type":36},"2024-09-01",{"date":605,"type":21},{"name":74,"class":75},{"id":631,"slug":632,"hasResults":11,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":4,"eligibilityCriteria":636,"healthyVolunteers":16,"sex":265,"minAge":637,"maxAge":4,"enrollmentInfo":638,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":640,"conditions":641,"keywords":642,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":256},"100536840","evaluation-of-telemedicine-medical-abortion-service-in-ecuador-100536840","NCT06270056","Evaluation of Telemedicine Medical Abortion Service in Ecuador","Evaluation of Telemedicine Services to Address Urgent Issues Related to Sexual and Reproductive Rights in Ecuador","Inclusion Criteria:\n\n* Woman is seeking abortion care and wants to use telemedicine service for her medication abortion procedure.\n* Woman has access to an internet connection or a device that allows remote consultation.\n* Woman is 15 years of age or older.\n* Woman can provide an address to which abortion medications will be mailed.\n* Woman reports having no contraindications to a medical abortion.\n* The study provider does not suspect ectopic pregnancy or a nonviable pregnancy.\n* The gestational age allows sufficient time for the woman to take the misoprostol no later than 84 days of gestation.\n* A feasible plan is made that the woman agrees to confirm complete abortion and to seek care to manage incomplete abortion complications.\n* The woman understands the study procedures and is likely to comply with study instructions and has granted informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Medically ineligible for procedure.\n* Provider determines that a medical abortion using the telemedicine approach is not appropriate for that person.","15 Years",{"count":639,"type":21},100,"This research seeks to demonstrate that a telemedicine model for the provision of legal abortion services in Ecuador is safe, feasible and acceptable to users requesting a medication abortion and who are less than 12 weeks pregnant.",[270],[643],"abortion","2024-10-11",{"date":646,"type":36},"2024-10-15",{"date":648,"type":36},"2024-07-24",{"date":650,"type":21},"2025-09",{"name":652,"class":75},"Gynuity Health Projects",{"id":654,"slug":655,"hasResults":11,"nctId":656,"briefTitle":657,"officialTitle":657,"acronym":4,"eligibilityCriteria":658,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":659,"targetDuration":4,"studyType":55,"phases":660,"briefSummary":661,"conditions":662,"keywords":665,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":670,"lastUpdatePostDateStruct":671,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":676,"locationsCount":76},"100561677","pain-perception-in-protection-of-the-palatal-donor-area-after-harvesting-a-free-gingival-graft-using-flowable-resin-versus-a-self-adhesive-dressing-100561677","NCT06593275","Pain Perception in Protection of the Palatal Donor Area After Harvesting a Free Gingival Graft Using Flowable Resin Versus a Self-adhesive Dressing","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Patients with plaque control less than 20%\n* Patients with bleeding on probing less than 10%\n* Patients in need of periodontal or peri-implant surgery in the upper or lower jaw\n* Not having previous surgeries in the donor area\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding patients\n* Patients with lesions in the palate\n* Patients who use prostheses that cover the palate\n* Patients with active periodontal disease\n* Patients who smoke\n* Patients with systemic diseases\n* Torus palatinus\n* Patients with a history of chemotherapy and radiotherapy",{"count":150,"type":21},[57],"The use of a connective tissue graft harvested from the palate is currently one of the most effective and predictable alternatives for the correction of periodontal and peri-implant defects, but the discomfort generated in the palate is sometimes greater than mucogingival surgery. For this reason, we found the need to use different materials for palatal protection. In one group we will use light-cured fluid resin compared to another group a self-adhesive dressing to check which of these materials provides less postoperative pain generated by the harvest of a free gingival graft.",[663,664],"Perception of Pain","Protection of the Palate",[666,667,668,669],"protection of the palate","pain palate","flow resine","self-adhesive dressing","2024-10-07",{"date":672,"type":36},"2024-10-10",{"date":674,"type":21},"2024-10-30",{"date":605,"type":21},{"name":74,"class":75},{"id":678,"slug":679,"hasResults":11,"nctId":680,"briefTitle":681,"officialTitle":682,"acronym":4,"eligibilityCriteria":683,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":684,"enrollmentInfo":685,"targetDuration":4,"studyType":55,"phases":686,"briefSummary":687,"conditions":688,"keywords":691,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":697,"lastUpdatePostDateStruct":698,"startDateStruct":700,"completionDateStruct":702,"leadSponsor":704,"locationsCount":76},"100523997","endoscopic-ultrasound-shear-wave-for-liver-fibrosis-in-masld-patients-the-rumipamba-trial-100523997","NCT06102980","Endoscopic Ultrasound Shear Wave for Liver Fibrosis in MASLD Patients: The RUMIPAMBA Trial","Estimation of Liver Fibrosis in Patients With MASLD Screening Criteria Through Endoscopic Ultrasound-guided Shear Wave vs Transabdominal Ultrasound and Transient Elastography: The RUMIPAMBA Diagnostic Trial","Inclusion Criteria:\n\n* Patients referred for any kind of endoscopic procedure.\n* Without clinical suspicion of advanced liver fibrosis.\n* Acceptance to participate in the study.\n\nExclusion Criteria:\n\n* History of greater amounts of alcohol per week (140 g\u002Fweek and 210 g\u002Fweek for females and males respectively).\n* Significant or advanced fibrosis by Fibrosis-4 Index (FIB4) or the aspartate aminotransferase to platelet ratio index (APRI).\n* Any liver space-occupying lesion in the US.\n* Comorbidities or conditions related to avoidance of interventional procedures, namely: pregnancy or nursing, coagulopathy or any risk of bleeding, Anaesthesiology Society Association classification IV or higher, New York Heart Association functional class III or IV.","79 Years",{"count":150,"type":21},[57],"Currently, there is no description of the contribution of the endoscopic ultrasound (EUS)-guided shear wave elastography (SWE) when describing liver fibrosis in patients with screening criteria of metabolic dysfunction-associated steatotic liver disease (MASLD), with absent-to-mild liver fibrosis. Similar research has been published but using vibration-controlled transient elastography (VCTE), recommended mainly due to its lower cost and less invasiveness. However, VCTE is limited to the anatomical proportions of the patient's body, and cannot assess the right hepatic lobe with less reliability, contrary to the EUS-SWE.",[689,690],"Liver Steatosis","Fibrosis, Liver",[692,693,694,695,696],"Liver steatosis","Fatty liver","Endosonography","Elastography","Liver fibrosis","2024-09-22",{"date":699,"type":36},"2024-09-24",{"date":701,"type":36},"2023-11-01",{"date":703,"type":21},"2025-04-01",{"name":705,"class":75},"Instituto Ecuatoriano de Enfermedades Digestivas",{"id":707,"slug":708,"hasResults":11,"nctId":709,"briefTitle":710,"officialTitle":711,"acronym":4,"eligibilityCriteria":712,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":713,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":715,"conditions":716,"keywords":723,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":725,"lastUpdatePostDateStruct":726,"startDateStruct":728,"completionDateStruct":730,"leadSponsor":732,"locationsCount":76},"100503374","omic-technologies-applied-to-the-study-of-b-cell-lymphoma-for-the-discovery-of-diagnostic-and-prognosis-biomarkers-100503374","NCT05834426","Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers","Omic Technologies Applied to the Study of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers","Inclusion Criteria:\n\n* 18 years and older;\n* Both sexes;\n* Patients with confirmed histopathological diagnosis of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma;\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2;\n* Patient intending to receive full-dose treatment (Monoclonal antibodies plus anthracycline based combination chemotherapy);\n* Staged with PET-CT or CT.\n\nExclusion Criteria:\n\n* Patients with comorbidities that may interfere with the interpretation of the results (CKD in dialysis phase, Autoimmune diseases, uncontrolled Diabetes Mellitus (DM), symptomatic Heart Failure (CHF), HIV positive, positive serology for hepatitis B and C);\n* Patients requiring multiple blood transfusions (4 or more blood components for the same period or cause);\n* Pregnant women;\n* First-line treatment in another institution;\n* Diffuse transformed Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma",{"count":714,"type":21},50,"The goal of this observational study is to determine the plasma metabolomic profile in diffuse large B-cell lymphoma and high-grade B lymphomas patients before, during and after treatment by ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)",[717,718,537,719,720,721,722],"Lymphoma, B-Cell","Neoplasms","High-grade B-cell Lymphoma","Diffuse Large B Cell Lymphoma","Non Hodgkin Lymphoma","Metabolomics",[724],"Metabolomic Analysis","2023-06-19",{"date":727,"type":36},"2023-06-22",{"date":729,"type":21},"2023-09-01",{"date":731,"type":21},"2026-08-31",{"name":733,"class":75},"Sociedad de Lucha Contra el Cáncer del Ecuador",""]